Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2018 1
2019 5
2020 7
2021 11
2022 20
2023 13
2024 8
2025 4
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators. McGarvey LP, et al. Lancet. 2022 Mar 5;399(10328):909-923. doi: 10.1016/S0140-6736(21)02348-5. Lancet. 2022. PMID: 35248186 Clinical Trial.
BACKGROUND: Gefapixant is an oral P2X(3) receptor antagonist that has previously shown efficacy and safety in refractory chronic cough and unexplained chronic cough. We therefore aim to confirm the efficacy and safety of gefapixant in participants with …
BACKGROUND: Gefapixant is an oral P2X(3) receptor antagonist that has previously shown efficacy and safety in refractory chronic c …
The Clinical Approach to Chronic Cough.
Satia I, Hassan W, McGarvey L, Birring SS. Satia I, et al. J Allergy Clin Immunol Pract. 2025 Mar;13(3):454-466. doi: 10.1016/j.jaip.2024.11.004. Epub 2024 Nov 16. J Allergy Clin Immunol Pract. 2025. PMID: 39557290 Free article. Review.
In recent years, efforts have intensified to elucidate the mechanisms underlying chronic cough and to focus on investigating and treating refractory chronic cough (RCC). A "treatable trait" approach, which focuses on identifying and addressing the specific associate …
In recent years, efforts have intensified to elucidate the mechanisms underlying chronic cough and to focus on investigating and trea …
Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
Muccino D, Green S. Muccino D, et al. Pulm Pharmacol Ther. 2019 Jun;56:75-78. doi: 10.1016/j.pupt.2019.03.006. Epub 2019 Mar 14. Pulm Pharmacol Ther. 2019. PMID: 30880151 Review.
Gefapixant, a first-in-class, non-narcotic, selective antagonist of the P2X3 receptor, recently demonstrated efficacy and was generally well tolerated in phase 2 clinical trials in patients with RCC, validating the utility of targeting this receptor in patients with …
Gefapixant, a first-in-class, non-narcotic, selective antagonist of the P2X3 receptor, recently demonstrated efficacy and was …
Real-world usage and response to gefapixant in refractory chronic cough.
Matsumoto H, Kanemitsu Y, Ohe M, Tanaka H, Terada K, Nishi K, Atsuta R, Hara J, Saito J, Ohmichi M, Ishizuka T, Nishiuma T, Inoue H, Watanabe N, Nagano T, Ueda T, Ogawa H, Endo S, Suzuki T, Kita T, Fujimori K, Ishiura Y, Fujimura M, Niimi A. Matsumoto H, et al. ERJ Open Res. 2025 Jul 7;11(4):01037-2024. doi: 10.1183/23120541.01037-2024. eCollection 2025 Jul. ERJ Open Res. 2025. PMID: 40630384 Free PMC article.
BACKGROUND: The real-world efficacy of the P2X3 antagonist gefapixant, a new class of antitussive for refractory chronic cough, is not yet fully understood. This study aimed to evaluate the real-world usage and response to gefapixant in patients with r …
BACKGROUND: The real-world efficacy of the P2X3 antagonist gefapixant, a new class of antitussive for refractory chronic co …
The Therapeutic Landscape in Chronic Cough.
Smith JA. Smith JA. Lung. 2024 Feb;202(1):5-16. doi: 10.1007/s00408-023-00666-y. Epub 2023 Dec 21. Lung. 2024. PMID: 38127133 Free PMC article. Review.
In recent years, there has been a substantial increase in the development of antitussive therapies and the first new therapy, gefapixant has been licenced in Europe. This review describes current unlicenced treatments for chronic cough and details treatments current …
In recent years, there has been a substantial increase in the development of antitussive therapies and the first new therapy, gefapixant …
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, Li YP, Wu WC, Xu ZJ, Muccino DR, Ford AP; Protocol 012 Investigators. Smith JA, et al. Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25. Lancet Respir Med. 2020. PMID: 32109425 Clinical Trial.
BACKGROUND: Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. ...At 12 weeks, patients' geometric mean awake cough frequency was 18.2 coughs per h (geometric SD 3.1) wi …
BACKGROUND: Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained ch …
Chronic cough relief by allosteric modulation of P2X3 without taste disturbance.
Guo CR, Zhang ZZ, Zhou X, Sun MY, Li TT, Lei YT, Gao YH, Li QQ, Yue CX, Gao Y, Lin YY, Hao CY, Li CZ, Cao P, Zhu MX, Rong MQ, Wang WH, Yu Y. Guo CR, et al. Nat Commun. 2023 Sep 20;14(1):5844. doi: 10.1038/s41467-023-41495-0. Nat Commun. 2023. PMID: 37730705 Free PMC article.
Here, we uncover a mechanism of allosteric regulation of P2X3 in the inner pocket of the head domain (IP-HD), and show that the antitussive effects of quercetin and PSFL2915 (our nM-affinity P2X3 inhibitor optimized based on quercetin) on male mice and guinea pigs w …
Here, we uncover a mechanism of allosteric regulation of P2X3 in the inner pocket of the head domain (IP-HD), and show that the antit …
Exploring the Potential of a P2X3 Receptor Antagonist: Gefapixant in the Management of Persistent Cough Associated with Interstitial Lung Disease.
Takahashi T, Saito A, Yorozuya T, Nishikiori H, Kuronuma K, Chiba H. Takahashi T, et al. Medicina (Kaunas). 2025 May 14;61(5):892. doi: 10.3390/medicina61050892. Medicina (Kaunas). 2025. PMID: 40428850 Free PMC article.
Gefapixant, a P2X3 receptor antagonist, can potentially alleviate chronic cough by inhibiting the ATP-mediated activation of sensory C-fibers, but its efficacy in ILD-associated cough remains unclear. ...Cough frequency, Leicester Cough Q …
Gefapixant, a P2X3 receptor antagonist, can potentially alleviate chronic cough by inhibiting the ATP-mediated activati …
The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
Morice AH, Kitt MM, Ford AP, Tershakovec AM, Wu WC, Brindle K, Thompson R, Thackray-Nocera S, Wright C. Morice AH, et al. Eur Respir J. 2019 Jul 4;54(1):1900439. doi: 10.1183/13993003.00439-2019. Print 2019 Jul. Eur Respir J. 2019. PMID: 31023843 Free article. Clinical Trial.
We evaluated the effect of gefapixant on cough reflex sensitivity to evoked tussive challenge.In this phase 2, double-blind, two-period study, patients with chronic cough (CC) and healthy volunteers (HV) were randomised to single-dose gefapixant 100 mg …
We evaluated the effect of gefapixant on cough reflex sensitivity to evoked tussive challenge.In this phase 2, double-blind, t …
P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough.
Cui WW, Wang SY, Zhang YQ, Wang Y, Fan YZ, Guo CR, Li XH, Lei YT, Wang WH, Yang XN, Hattori M, Li CZ, Wang J, Yu Y. Cui WW, et al. Comput Struct Biotechnol J. 2022 Mar 31;20:1642-1653. doi: 10.1016/j.csbj.2022.03.030. eCollection 2022. Comput Struct Biotechnol J. 2022. PMID: 35465163 Free PMC article.
Gefapixant/AF-219, a selective inhibitor of the P2X3 receptor, is the first new drug other than dextromethorphan to be approved for the treatment of refractory chronic cough (RCC) in nearly 60 years. ...We previously identified the site and mechanism of actio …
Gefapixant/AF-219, a selective inhibitor of the P2X3 receptor, is the first new drug other than dextromethorphan to be approve …
67 results